Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03527186 · ClinicalTrials.gov registry record · Phase 1
Comparative Bioavailability of Risperidone
A Phase 1 study of Schizophrenia, sponsored by Rovi Pharmaceuticals Laboratories.
- Completed
- Registry status
- Phase 1
- Development phase
- 81
- Enrollment target
- 2
- Study locations
NCT03527186 is a Phase 1 study of Schizophrenia that has completed, run by Rovi Pharmaceuticals Laboratories. The registered enrollment target is 81 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (63% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT03527186, a Phase 1 study of Schizophrenia, has completed, sponsored by Rovi Pharmaceuticals Laboratories.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 81 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is an open-label, one sequence study to evaluate the steady-state comparative bioavailability of 100 mg Risperidone ISM® injectable every 4 weeks compared to once daily 4 mg oral risperidone in subjects with schizophrenia stabilized on oral risperidone treatment.
Conditions Studied
Interventions
- DRUG Risperidone ISM® 100 mg
Study Locations (2)
California
- Collaborative Neuroscience Network - Long Beach
New Jersey
- Hassman Research Institute - Berlin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2018-07-09 |
| Est. Completion | 2019-04-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03527186
The ClinicalTrials.gov registry entry for NCT03527186 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (63% lower). The listed sponsor is Rovi Pharmaceuticals Laboratories, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 1 intervention - of which Risperidone ISM® 100 mg is the first listed.
NCT03527186 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, New Jersey.
Frequently Asked Questions
What is clinical trial NCT03527186 about?
NCT03527186 is a clinical study titled "Comparative Bioavailability of Risperidone". This is an open-label, one sequence study to evaluate the steady-state comparative bioavailability of 100 mg Risperidone ISM® injectable every 4 weeks compared to once daily 4 mg oral risperidone in subjects with schizophrenia stabilized on oral risperidone treatment.
What is the current status of trial NCT03527186?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 81 participants. The study started on 2018-07-09. Estimated completion is 2019-04-06.
What conditions does trial NCT03527186 study?
This clinical trial studies the following conditions: Schizophrenia.
What interventions are being tested in trial NCT03527186?
The interventions under investigation include: Risperidone ISM® 100 mg (DRUG).
Who is sponsoring clinical trial NCT03527186?
This trial is sponsored by Rovi Pharmaceuticals Laboratories, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03527186 being conducted?
This trial has 2 study locations across California, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Tolerability of MDMA in Schizophrenia
RECRUITING · Phase 1
-
Imaging Synapses With [11C] UCB-J in the Human Brain
RECRUITING · Phase 1
-
A Study to Evaluate the Dose Levels, Safety, and Drug Levels of Single KarXT Intramuscular Injection in Participants With Schizophrenia
RECRUITING · Phase 1
-
Proposal To Develop A Rapid And Cost-Effective Diagnostic Test For Schizophrenia
RECRUITING · Phase 1
-
Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder
RECRUITING · Phase 1
-
Genetics of Cannabis Use Disorder and Cannabinoid Response in Humans
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.